Health informatics system aids timely, equitable diabetes care
A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.
Obesity as prevalent in type 1 diabetes as general US population
There is a “substantial” burden of overweight and obesity among people with type 1 diabetes, say US researchers who found rates to be in line with that of the general population.
TriMaster data support ‘try before you choose’ for type 2 diabetes medications
Allowing people to trial medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication.
Meta-analysis backs SGLT2 inhibitors for kidney disease
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.
Real-world adjunctive medication outcomes in type 1 diabetes revealed
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
Diabetes ‘no longer a CVD risk equivalent’
The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.
Cost drives one in six US adults to ration insulin
Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.
First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’
Researchers calculate that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” to make them cost effective first-line treatments in the USA.
People with type 2 diabetes and CKD missing out on renoprotective drugs
People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.
Common diabetic peripheral neuropathic pain treatments equivalent in OPTION-DM
Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.